ArticleWorld journal of experimental medicine2026
Antidiabetic effects of
Article in World journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration of the Potential Mechanisms of Anaphalis virgata Extract in Treating Diabetic Hepatic Injury Based on Network Pharmacology and Experimental Validation.Chemistry & biodiversity · 2026Article
- Letter to the Editor: Endocrine determinants of diabetic ketoacidosis outcomes in type 2 diabetes and insights into Gymnema sylvestre actions.World journal of experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia. Metformin is the standard therapy, however plant-based adjuncts such as
aimTo evaluate the anti-diabetic effects of GS, alone and with metformin, on glycemic control, lipid profile, renal function, and body weight in high-fat diet and streptozotocin (STZ)-induced T2DM rats.
methodsThirty male Sprague Dawley rats (150 ± 20 g) were divided into five groups: Normal control, diabetic control (DC), metformin-treated, GS-treated, and combination-treated (metformin + GS). T2DM was induced by 21 days of high-fat diet followed by two STZ injections (25 mg/kg, five days apart). Rats with fasting blood glucose (FBG) ≥ 270 mg/dL were treated for 28 days. Biochemical parameters (FBG, glycated hemoglobin, serum creatinine, and cholesterol) and body weight were assessed.
resultsBy day 28, all treatment groups showed significant improvements compared to DC. Metformin produced the greatest reductions in FBG, cholesterol, creatinine, and glycated hemoglobin. GS monotherapy had modest but significant effects, while metformin + GS improved glycemic control and lipid profile more effectively than GS alone. Metformin remained superior in renal protection. All treated groups showed significantly higher body weights than DC, indicating protection against STZ-induced weight loss.
conclusionThis study demonstrated that metformin and GS, individually and in combination, improved glycemic control and metabolic outcomes in T2DM rats. While metformin showed the greater efficacy, combination therapy provided additive benefits, supporting GS as a potential adjunct in T2DM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.